07.10.25 -- Lessons In Automation With Roswell Park Comprehensive Cancer Center's Christopher Choi, Ph.D.

Here, we illustrate how our Design of Experiment (DoE) can accelerate development timelines, lower costs, and enhance decision-making across cell therapy programs.

Discover how an automated cryopreservation process is reshaping the leukapheresis supply chain and driving progress in the future of cell and gene therapy.

In this conversation, Dr. Boro Dropulić, Executive Director of Caring Cross, shares his perspective on regional challenges, opportunities for innovation, and the role of global partnerships.

Discover a scalable, cost-effective solution for gene therapy manufacturing with VintaProcess™ — featuring VintaCell™, VintaFect™, and fixed-bed bioreactor technology.

Accelerate the development of high-quality biopharmaceuticals by implementing phase-appropriate, risk-based manufacturing and testing strategies that ensure timely progression.

Ensure the success of your tech transfer by addressing these key challenges and optimizing your processes for seamless scalability and compliance.

Understanding these synergies and their impact on efficiency, safety, and cost-effectiveness is essential for stakeholders navigating the complexities of CGT development and production.

Gain insight into these end-to-end plasmid DNA solutions, leveraging robust cGMP-compliant processes and single-use manufacturing platforms to accelerate your cell and gene therapy programs.

Consider several gene editing technologies — TARGATT, Mad7, and Base Editing — and gain insights into their transformative applications in genetic engineering and therapeutic development.

Ensure your business stays ahead in today’s complex regulatory environment by implementing robust regulatory affairs strategies that streamline compliance and product approvals.

Growth in rAAV-based therapies is creating a need for dramatically increased production. Learn how AAV productivity can be optimized using platform technologies capable of affording significantly higher titers.